APA (7th ed.) Citation

Chen, P., Wang, M., Peng, S., Zhu, H., Wang, Y., Wan, Z., . . . Zhou, Y. (2026). Comparative Efficacy and Safety of First-Line Immune Checkpoint Inhibitors Plus Chemotherapy with or Without Bevacizumab in Advanced Non-Squamous Non-Small Cell Lung Carcinoma. Current Oncology, 31(3), 173. https://doi.org/10.3390/curroncol33030173

Chicago Style (17th ed.) Citation

Chen, Ping, Mengchi Wang, Siyan Peng, Honglin Zhu, Yanming Wang, Zixuan Wan, Xuan Yang, Zhixin Yu, and Yixin Zhou. "Comparative Efficacy and Safety of First-Line Immune Checkpoint Inhibitors Plus Chemotherapy with or Without Bevacizumab in Advanced Non-Squamous Non-Small Cell Lung Carcinoma." Current Oncology 31, no. 3 (2026): 173. https://doi.org/10.3390/curroncol33030173.

MLA (9th ed.) Citation

Chen, Ping, et al. "Comparative Efficacy and Safety of First-Line Immune Checkpoint Inhibitors Plus Chemotherapy with or Without Bevacizumab in Advanced Non-Squamous Non-Small Cell Lung Carcinoma." Current Oncology, vol. 31, no. 3, 2026, p. 173, https://doi.org/10.3390/curroncol33030173.